We validated the use of combinatorial strategies using novel activator domains for powerful gene activation in a proof of concept TSG MASPIN and in the context of a novel TSG, REPRIMO, which are both silenced by DNA methylation in aggressive tumor cells. The gene discussed is SERPINB5; the disease is neoplasm.